Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.

被引：7

作者：

Bahary, Nathan

Garrido-Laguna, Ignacio

Wang-Gillam, Andrea

Nyak-Kapoor, Asha

Kennedy, Eugene

Vahanian, Nicholas N.

Link, Charles J.

机构：

[1] Univ Pittsburgh, Med Ctr Canc Pavil, Pittsburgh, PA USA

[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[3] Washington Univ, Sch Med, St Louis, MO USA

[4] GRU Canc Ctr, Augusta, GA USA

[5] NewLink Genet, Ames, IA USA

[6] NewLink Genet Corp, Ames, IA USA

来源：

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.452

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

452

引用

页数：1